Bavarian Nordic A/S

Showcase Sponsor

Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE, a non-replicating smallpox vaccine, approved in the European Union under the trade name IMVANEX® for active immunization of adults and also approved in Canada for active immunization in a public health emergency of adults that are contraindicated to replicating smallpox vaccines. Phase 3 trials are ongoing in the U.S. where the vaccine is also supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government.